Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire February 11, 2019

Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer

GlobeNewswire January 3, 2019

Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire January 2, 2019

Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11

GlobeNewswire December 3, 2018

Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results

GlobeNewswire November 7, 2018

Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility

GlobeNewswire November 5, 2018

Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire October 1, 2018

Arcturus Therapeutics to Present at October Investor Conferences

GlobeNewswire September 25, 2018

Arcturus Therapeutics Expands Management Team

GlobeNewswire September 21, 2018

Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor

GlobeNewswire August 29, 2018

Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer

GlobeNewswire August 28, 2018

Arcturus Therapeutics to Present at Three Investor Conferences in September

GlobeNewswire August 27, 2018

LD Micro Index Celebrates Three Years

Accesswire August 1, 2018

Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics

GlobeNewswire July 23, 2018

Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018

GlobeNewswire July 20, 2018

Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

GlobeNewswire July 9, 2018

Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 18, 2018

Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO

GlobeNewswire May 31, 2018

Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders

GlobeNewswire May 30, 2018

Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne

GlobeNewswire May 29, 2018